Compare ATRA & IINN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRA | IINN |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 35.3M |
| IPO Year | 2014 | N/A |
| Metric | ATRA | IINN |
|---|---|---|
| Price | $5.42 | $0.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $2.00 |
| AVG Volume (30 Days) | 142.1K | ★ 388.3K |
| Earning Date | 04-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.93 | N/A |
| Revenue | ★ $128,940,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9,715.95 |
| P/E Ratio | $1.85 | ★ N/A |
| Revenue Growth | ★ 1404.02 | N/A |
| 52 Week Low | $3.92 | $0.40 |
| 52 Week High | $19.15 | $1.65 |
| Indicator | ATRA | IINN |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 35.95 |
| Support Level | $4.06 | $0.55 |
| Resistance Level | $5.71 | $0.67 |
| Average True Range (ATR) | 0.49 | 0.03 |
| MACD | 0.38 | 0.01 |
| Stochastic Oscillator | 71.07 | 52.33 |
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.